[
    {
        "outcome_uid": "42525beb",
        "clinical_question": "What are the effects of non\u2013vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?",
        "population": "Adults and/or children with CKD and atrial fibrillation",
        "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone",
        "comparator": "Warfarin, placebo",
        "outcome": "Intracranial hemorrhage (follow-up: range 1.9 years to 2.8 years)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "c0f8d542",
            "1cd94b34",
            "e3444fca"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "There were only 91 events across the 5945 participants enrolled in the 3 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."
                },
                "Other considerations": {
                    "result": "publication bias strongly suspected",
                    "rationales": "Only some of the 7 studies reported on outcome."
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "NOAC": "32/2981 (1.1%)",
                    "Warfarin": "59/2964 (2.0%)"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "HR 0.60 (0.34 to 1.05)()",
                    "Absolute Effect (95% CI)": "8 fewer per 1,000 (from 13 fewer to 1 more)()"
                }
            }
        }
    },
    {
        "outcome_uid": "965eafb5",
        "clinical_question": "What are the effects of non\u2013vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?",
        "population": "Adults and/or children with CKD and atrial fibrillation",
        "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone",
        "comparator": "Warfarin, placebo",
        "outcome": "Major bleeding (factor Xa inhibitors) (follow-up: range 6 months to 2.8 years)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "c0f8d542",
            "bc897c67",
            "1cd94b34",
            "54a711dd",
            "e3444fca",
            "e152d0a8"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "There were some concerns with the risk of bias, particularly with the reporting of selected results and the potential for missing data."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "NOAC": "NE",
                    "Warfarin": "NE"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "HR 0.73 (0.58 to 0.92)()",
                    "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 1 fewer to 1 fewer)()"
                }
            }
        }
    },
    {
        "outcome_uid": "bed07c18",
        "clinical_question": "What are the effects of non\u2013vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?",
        "population": "Adults and/or children with CKD and atrial fibrillation",
        "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone",
        "comparator": "Warfarin, placebo",
        "outcome": "Major bleeding (factor IIa inhibitors) (follow-up: median 1.8 years)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "24f8f876"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "There was some statistical heterogeneity in the meta-analysis results (I2 = 50%)."
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "Only one study addressed this outcome for this comparison."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "The total number of events among the participants enrolled in the trial is estimated to be less than the number needed to reach the optimal information size (i.e., 300). The number of events and the number of participants were not reported."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "NOAC": "NE",
                    "Warfarin": "NE"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "HR 1.11 (0.97 to 1.27)()",
                    "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 1 fewer to 1 fewer)()"
                }
            }
        }
    },
    {
        "outcome_uid": "dbc34756",
        "clinical_question": "What are the effects of non\u2013vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?",
        "population": "Adults and/or children with CKD and atrial fibrillation",
        "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone",
        "comparator": "Warfarin, placebo",
        "outcome": "Clinically-relevant non-major bleeding (follow-up: range 1.9 years to 2.5 years)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "bc897c67",
            "1cd94b34",
            "54a711dd",
            "e3444fca"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "publication bias strongly suspected",
                    "rationales": "Only some of the 7 studies reported on outcome."
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "NOAC": "346/1803 (19.2%)",
                    "Warfarin": "334/1752 (19.1%)"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "HR 1.06 (0.86 to 1.31)()",
                    "Absolute Effect (95% CI)": "10 more per 1,000 (from 24 fewer to 51 more)()"
                }
            }
        }
    }
]